CoChat

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

Open access
Forsell, Pontus, Parrado Fernández, Cristina, Nilsson, Boel, Sandin, Johan, Nordvall, Gunnar, Segerdahl, Märta · 2024 · Pharmaceuticals

The DOI matches its Crossref record; 184 of the 185 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Neurotrophins are important regulators of neuronal and non-neuronal functions. As such, the neurotrophins and their receptors, the tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases, has attracted intense research interest and their role in multiple diseases including Alzheimer’s disease has been described. Attempts to administer neurotrophins to patients have been reported, but the clinical trials have so far have been hampered by side effects or a lack of clear efficacy. Thus, much of the focus during recent years has been on identifying small molecules acting as agonists or positive allosteric modulators (PAMs) of Trk receptors. Two examples of successful discovery and development of PAMs are the TrkA-PAM E2511 and the pan-Trk PAM ACD856. E2511 has been reported to have disease-modifying effects in preclinical models, whereas ACD856 demonstrates both a symptomatic and a disease-modifying effect in preclinical models. Both molecules have reached the stage of clinical development and were reported to be safe and well tolerated in clinical phase 1 studies, albeit with different pharmacokinetic profiles. These two emerging small molecules are interesting examples of possible novel symptomatic and disease-modifying treatments that could complement the existing anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. This review aims to present the concept of positive allosteric modulators of the Trk receptors as a novel future treatment option for Alzheimer’s disease and other neurodegenerative and cognitive disorders, and the current preclinical and clinical data supporting this new concept. Preclinical data indicate dual mechanisms, not only as cognitive enhancers, but also a tentative neurorestorative function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph17080997

Cites

184 of 185 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A schematic timeline showing a selection of major achievements in the identification or development of positive modulators of neurotrophin signaling including publication of scientific articles, submission of patent applications or performed clinical trials.
Figure 1 A schematic timeline showing a selection of major achievements in the identification or development of positive modulators of neurotrophin signaling including publication of scientific articles, submission of patent applications or performed clinical trials.CC BY · PubMed Central
Figure 2 (a) A schematic representation of Trk receptor expression summarized from [21,24,25,26,27] and the Human Protein Atlas initiative (https://www.proteinatlas.org, accessed on 16 June 2024) where red indicates high levels and blue indicates low levels of expression. Figures (b,c) are RNAseq data from Allen Brain Map, Allen Institute for Brain Science; Human multiple cortical areas—SMART-seq (https://celltypes.brain-map.org/rnaseq, accessed on 16 June 2024). (b) This data set includes single-nucleus transcriptomes from 49,495 nuclei across multiple human cortical areas. Individual layers of cortex were dissected from tissues covering the middle temporal gyrus. (c) The data set includes single-cell transcriptomes from 76,533 total cells derived from two post-mortem human brain specimens in the primary motor cortex.
Figure 2 (a) A schematic representation of Trk receptor expression summarized from [21,24,25,26,27] and the Human Protein Atlas initiative (https://www.proteinatlas.org, accessed on 16 June 2024) where red indicates high levels and blue indicates low levels of expression. Figures (b,c) are RNAseq data from Allen Brain Map, Allen Institute for Brain Science; Human multiple cortical areas—SMART-seq (https://celltypes.brain-map.org/rnaseq, accessed on 16 June 2024). (b) This data set includes single-nucleus transcriptomes from 49,495 nuclei across multiple human cortical areas. Individual layers of cortex were dissected from tissues covering the middle temporal gyrus. (c) The data set includes single-cell transcriptomes from 76,533 total cells derived from two post-mortem human brain specimens in the primary motor cortex.CC BY · PubMed Central
Figure 3 Schematic representation of Trk signaling pathways. The arrows on the upper part indicate suggested sites for interaction between small-molecule modulators and Trk receptors. Phosphotyrosine residues on TrkA are highlighted in yellow circles. Some phosphotyrosine residues are numbered according to the amino acid sequence of TrkA and their interaction with adaptor proteins SHC1, PI3K, and PLCγ are indicated. Functional outcomes are depicted in light blue boxes with citations in square brackets. The figure was created with BioRender.com (https://biorender.com, accessed on 16 June 2024).
Figure 3 Schematic representation of Trk signaling pathways. The arrows on the upper part indicate suggested sites for interaction between small-molecule modulators and Trk receptors. Phosphotyrosine residues on TrkA are highlighted in yellow circles. Some phosphotyrosine residues are numbered according to the amino acid sequence of TrkA and their interaction with adaptor proteins SHC1, PI3K, and PLCγ are indicated. Functional outcomes are depicted in light blue boxes with citations in square brackets. The figure was created with BioRender.com (https://biorender.com, accessed on 16 June 2024).CC BY · PubMed Central
Figure 4 Schematic view of different possible therapeutic modalities on Alzheimer’s disease progression.
Figure 4 Schematic view of different possible therapeutic modalities on Alzheimer’s disease progression.CC BY · PubMed Central
Figure 5 A schematic representation of biomarkers and clinical course of AD and putative temporal treatment options for second-generation symptomatic or disease-modifying treatments.
Figure 5 A schematic representation of biomarkers and clinical course of AD and putative temporal treatment options for second-generation symptomatic or disease-modifying treatments.CC BY · PubMed Central
Figure 6 Chemical structure of compounds disclosed in patent applications of scientific journals.
Figure 6 Chemical structure of compounds disclosed in patent applications of scientific journals.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 14

Metadata

Authors
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M.
Affiliations
  • Karolinska Institutet (SE)
  • AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden
  • AlzeCure Pharma (Sweden) (SE)
Corresponding author
Forsell, Pontus
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2024-07-28
Volume
17
Issue
8
Pages
997
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4401209031
Cited by
14
References
184
Citations by year
2026: 7 · 2025: 7
FWCI
0.80
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
positive allosteric modulators, Trk receptors, Alzheimer's disease, neurotrophins, TrkA, disease-modifying therapy, symptomatic treatment, anti-amyloid monoclonal antibodies, cognitive enhancement, neurorestoration, neurodegenerative diseases, receptor tyrosine kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.